Target intelligence / Profile preview

Delta 4-desaturase, sphingolipid 2 (DEGS2)

Target
DEGS2
Molecular classification
Enzyme, Oxidoreductase (subtype: lipid desaturase and monooxygenase)
01

Overview

Delta 4-desaturase, sphingolipid 2 (DEGS2) is a bifunctional enzyme that acts as both a sphingolipid delta(4)-desaturase and a sphingolipid C4-hydroxylase, playing a crucial role in the biosynthesis of phytosphingolipids and ceramide in humans. DEGS2 is active in various tissues, especially in the skin, intestines, kidney, and brain. It regulates sphingolipid composition by catalyzing the formation of ceramide, a key structural and signaling lipid component. Genetic polymorphisms in DEGS2 have been linked to cognitive dysfunction in schizophrenia and to rare developmental syndromes such as Robinow syndrome. DEGS2 is part of the desaturase/hydroxylase enzyme family and its function is essential for proper sphingolipid metabolism and membrane integrity[1][2][3][4][5].

Other names
Sphingolipid delta(4)-desaturase/C4-hydroxylase DES2C14orf66DES2FADS8Degenerative spermatocyte homolog 2Sphingolipid C4-monooxygenaseDihydroceramide desaturase 2Sphingolipid 4-desaturaseSphingolipid delta(4)-desaturase 2Lipid desaturaseChromosome 14 open reading frame 66
02

Mechanism of action

Inhibition or modulation of enzymatic activity would affect sphingolipid metabolism and ceramide composition[1][2][4][5].

03

Biological functions

Sphingolipid biosynthesisCeramide formationCell signaling (via effects on sphingolipid composition)Maintenance of ceramide structure
04

Disease associations

Cognitive dysfunction (association with schizophrenia, cognition)Robinow syndrome (Autosomal Dominant 2 and 3)Other neurological and possibly skin barrier functions
05

Safety considerations

No well-characterized drug safety concerns, but gene loss or dysfunction may impact skin and neural tissues, affecting cognition and potential barrier function[1][2]
06

Biomarkers

Genetic polymorphisms (e.g., rs7157599, rs3783332) associated with altered expression and cognitive phenotypes[1]

Beyond the preview

Go deeper on Delta 4-desaturase, sphingolipid 2 (DEGS2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Delta 4-desaturase, sphingolipid 2 (DEGS2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call